BLAINJECTIONINJECTABLE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
FULPHILA (pegfilgrastim-jmdb) by Viatris (2) is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Approved for chemotherapy-induced neutropenia. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FULPHILA (pegfilgrastim-jmdb) is a biosimilar leukocyte growth factor approved in 2018 that reduces chemotherapy-induced neutropenia across 23 solid tumor and hematologic malignancies. It works by binding to cell surface receptors on hematopoietic cells to stimulate proliferation, differentiation, and functional activation. Administered as a subcutaneous injection, it is a pegylated granulocyte colony-stimulating factor (G-CSF) analog.
$0.624MPart D
PeakFULPHILA operates in a mature, competitive pegfilgrastim market with moderate claims volume; commercial teams face significant pricing and market-share pressure from established originator and biosimilar competitors.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications (1)
Career Relevance
FULPHILA represents a stable but highly competitive biosimilar opportunity; career roles emphasize commercial, market access, and supply chain expertise over clinical development. Viatris backing provides scale, but crowded oncology supportive care market limits growth trajectory.
Worked on FULPHILA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.